1 and 301 (33%) women were assigned to receive methyldopa.

2  if hypertension was maintained), or 1000 mg methyldopa (a single dose, without dose escalation).

3 lties were associated with beta-blockers and methyldopa, as well as untreated HDP, suggesting confoun

4 strated by clinically approved drugs such as methyldopa, baclofen, and gabapentin in addition to smal

5                  Few women were eligible for methyldopa for severe hypertension (181 [1%] of 20 819)

6 ral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in

7 in the nifedipine group than in those in the methyldopa group (249 [84%] women vs 230 [76%] women; p=

8 he labetalol group, and 11 (4%) women in the methyldopa group were ineligible for treatment (because

9 etalol group, and three [1%] neonates in the methyldopa group) were stillborn.

10 28 [77%] women; p=0.05) or the labetalol and methyldopa groups (p=0.80).

11                                The (S)-alpha-methylDOPA hydrochloride is obtained after four steps wi

12       The dopa decarboxylase (Ddc) and alpha-methyldopa hypersensitive (amd) genes arose from an anci

13 ted levels of l-DOPA, and its metabolite 3-O-methyldopa, in all measured brain regions of dyskinetic

14                         All three oral drugs-methyldopa, nifedipine, and labetalol-are viable initial

15 s occurred after in-community treatment with methyldopa (one [2%] of 51; India only) and none occurre

16 n original asymmetric synthesis of (S)-alpha-methylDOPA proceeding by the concept of memory of chiral

17 primary outcome attainment than labetalol or methyldopa use.